Stockscreener 앱 받기
14.65
6.15%
-0.96
시간 외 거래:
14.65
전일 마감가:
$15.61
열려 있는:
$15.59
하루 거래량:
644.84K
Relative Volume:
0.57
시가총액:
$1.00B
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-5.3663
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-4.99%
1개월 성능:
+14.19%
6개월 성능:
+4.34%
1년 성능:
+2.66%
1일 변동 폭
$14.40
$15.94
1주일 범위
$14.03
$15.94
52주 변동 폭
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
14.65 | 1.00B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - GlobeNewswire
Mineralys Therapeutics Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq
Mineralys Therapeutics to Announce First Quarter 2025 - GlobeNewswire
Clinical-Stage Biotech Mineralys Therapeutics Sets Q1 Earnings Date: Key Updates on Hypertension Pipeline Expected - Stock Titan
Trend Tracker for (MLYS) - news.stocktradersdaily.com
Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM - MSN
Mineralys Therapeutics Inc [MLYS] Records 50-Day SMA of $12.99 - knoxdaily.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Renaissance Technologies LLC - Defense World
Director Makes Bold Move with Multi-Million Dollar Stock Purchase! - TipRanks
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Mineralys Therapeutics’ lorundrostat shows efficacy in NEJM-published study - MSN
Lorundrostat shows promise in hypertension trial By Investing.com - Investing.com South Africa
Mineralys Therapeutics (MLYS) Shares Advance on Promising Hypert - GuruFocus
Lorundrostat shows promise in hypertension trial - Investing.com
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) - The Manila Times
Mineralys Therapeutics Announces Publication of Pivotal - GlobeNewswire
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada
Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics chief medical officer sells $165,185 in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com
Mineralys Therapeutics Executives Sell Shares - TradingView
Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance
SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow
SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia
Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada
Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks
When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com
Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia
ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum
Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks
Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks
Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times
Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):